Anticoagulants boost cancer survival rates

Researchers pooled data from nine randomised controlled trials of anticoagulants involving 2185 patients with lung cancer.

They found no survival benefit at six months but the patients taking anticoagulants were 18% more likely to be alive after one year and 27% more likely to be alive after two years.